BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16611306)

  • 1. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
    Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
    Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
    Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
    Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population, based on the Mayo clinic prognostic model. Euricterus Project Management Group.
    Reisman Y; van Dam GM; Gips CH; Lavelle SM; Euricterus PM
    Hepatogastroenterology; 1997; 44(16):982-9. PubMed ID: 9261586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
    Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
    Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS
    Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
    Lu L; Xiao ZJ; Chen HS; Lin H; Han ZC
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):281-4. PubMed ID: 15949290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia.
    Yi S; Cui R; Li Z; An G; Qi J; Zou D; Zhang P; Chen H; Wang J; Chang H; Qiu L
    Chin Med J (Engl); 2014; 127(12):2327-31. PubMed ID: 24931251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
    Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
    Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
    Trivanović D; Petkovic M; Stimac D
    Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
    Peters HP; van den Brand JA; Wetzels JF
    Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
    Moreau AS; Sebti Y; Duhamel A; Roccaro AM; Coiteux V; Gastinne T; Le Friec G; Burwick N; Amiot L; Ho AW; Poulain S; Hennache B; Hunter ZR; Dessaint JP; Ghobrial IM; Treon SP; Facon T; Zorn E; Leleu X
    Eur J Haematol; 2008 Jun; 80(6):503-9. PubMed ID: 18331603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of Waldenström macroglobulinaemia--the experience of one centre].
    Adam Z; Pour L; Krejcí M; Korístek Z; Navrátil M; Krivanová A; Zahradová L; Hájek R
    Vnitr Lek; 2009 Jan; 55(1):9-17. PubMed ID: 19227950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
    Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
    Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.